Skip to main content
. 2022 Feb 13;17(2):153–176. doi: 10.1016/j.ajps.2022.02.001

Fig. 1.

Fig. 1

Various forms of CRISPR/Cas9 including plasmid, mRNA and RNPs that could be delivered to achieve significant gene editing to treat retinal dystrophies.